Key facts
- This page summarizes Daniel Patrick O'Day's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2025, 19:12.
Daniel Patrick O'Day - 10 Mar 2025 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- Chairman & CEO, Director
- Issuer ticker
- GILD
- Reported as of
- 10 Mar 2025
- Net transaction value
- -$1,363,387
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 19:12:43 UTC
- Prior SEC filing
- 06 Feb 2025
- Next SEC filing
- 02 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward S. Son by Power of Attorney for Daniel P. O'Day
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Patrick O'Day filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 06 Feb 2025.
- Current net transaction value: -$1,363,387.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GILD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +24,024
- Change %
- +3.9%
- Price
- Shares after
- 641,900
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
GILD
transaction
Common Stock
Tax liability
- Transaction value
- $1,363,387
- Shares
- -11,632
- Change %
- -1.8%
- Price
- $117.21
- Shares after
- 630,268
- Date
- 10 Mar 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -24,024
- Change %
- -23%
- Price
- Shares after
- 80,953
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,024
- Exercise price
- Footnotes
- F1, F2
GILD
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +169,690
- Change %
- Price
- $0.000000
- Shares after
- 169,690
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 169,690
- Exercise price
- $117.21
- Footnotes
- F3
GILD
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- Shares
- +38,395
- Change %
- +47%
- Price
- Shares after
- 119,348
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,395
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Footnote F2
The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Footnote F3
The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.